End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
155,930 CLP | 0.00% |
|
0.00% | +14.33% |
Jul. 12 | J&J: completes acquisition of Yellow Jersey for $1.25 billion | CF |
Jul. 11 | Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeutics | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an enterprise value anticipated at 4.12 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.33% | 361B | - | ||
+62.66% | 854B | C+ | ||
+40.42% | 636B | B | ||
+17.16% | 324B | B- | ||
+9.87% | 301B | C+ | ||
+15.66% | 247B | B+ | ||
+17.90% | 228B | B- | ||
+14.86% | 177B | C+ | ||
+0.45% | 164B | C+ | ||
+5.17% | 129B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJCL Stock
- Ratings Johnson & Johnson